Resolution of Thrombi in Left Atrial Appendage With Edoxaban
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Non-valvular (NV) atrial fibrillation (AF) increases the risk of stroke by approximately
fivefold. The atrial thrombi associated with AF are seen within the left atrial appendage
(LAA) in most cases (> 90%). Anticoagulation with a vitamin-K antagonist (VKA) is recommended
to prevent thromboembolic complications and to resolve thrombi. Non-VKA oral anticoagulants
(NOACs) have replaced the VKA for the thromboprophylaxis in patients with NVAF since 2010.
Therefore, NOAC can be the excellent alternative to VKA concerning resolving preexisting LAA
thrombi because of its rapid onset of action and no need of bridging with heparin. However,
there is still lack of data regarding the optimal treatment for patients with AF and thrombi
in LAA with NOAC. There are only several case reports of the efficacy of NOACs in resolving
LAA thrombi available.
Edoxaban, which has data showing efficacy and safety in thromboprophylaxis, can be the new
option for treatment of patients with AF and LAA thrombi. The purpose of this study is to
evaluate the efficacy of Edoxaban in resolving the LAA thrombi, which is related with
nonvalvular AF.
Phase:
Phase 4
Details
Lead Sponsor:
Keimyung University Dongsan Medical Center
Collaborator:
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company